ICM
ALNY icon

ISZO Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

ISZO Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-17,000
Closed -$1.37M – 13
2015
Q3 		$1.37M Sell
17,000
-52,350
-75% -$5.82M 0.78% 9
2015
Q2 		$8.31M Buy
69,350
+43,650
+170% +$5.22M 4.3% 5
2015
Q1 		$2.68M Buy
+25,700
New +$2.6M 1.31% 8

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

ISZO Capital Management's ALNY Position: Q4 2015 in Review

ISZO Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2015, closing a stake of 17,000 shares — an estimated $1.37M sold.

ISZO Capital Management first reported a position in ALNY in Q1 2015 and held it in 3 quarters. The position peaked at $8.31M in Q2 2015. 261 funds tracked by Wall St. Rank hold ALNY as of Q4 2015.

  • ISZO Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • ISZO Capital Management sold 17,000 Alnylam Pharmaceuticals shares in Q4 2015, an estimated $1.37M.
  • ISZO Capital Management first reported a position in Alnylam Pharmaceuticals in Q1 2015 and held it in 3 quarters.
  • ISZO Capital Management's Alnylam Pharmaceuticals position peaked at $8.31M in Q2 2015.
  • 261 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2015.

Based on ISZO Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.